Bevacizumab - Biologic Drug Details

Summary for bevacizumab

Tradenames:	1
High Confidence Patents:	24
Applicants:	6
BLAs:	6
Suppliers: see list	5
Recent Clinical Trials:	See clinical trials for bevacizumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bevacizumab

Recent Clinical Trials for bevacizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Miami	Phase 1/Phase 2
Nykode Therapeutics ASA	Phase 2
Chimerix	Phase 1

See all bevacizumab clinical trials

Recent Litigation for bevacizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
GENENTECH, INC. v. DR. REDDYS LABORATORIES, INC.	2023-11-17
Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd.	2023-10-20
Genentech, Inc. v. Biogen MA Inc.	2023-07-13

See all bevacizumab litigation

PTAB Litigation

Petitioner	Date
Illumina, Inc. et al.	2021-07-20
Laboratory Corporation of America Holdings et al.	2021-05-28
Quest Diagnostics Incorporated	2021-04-15

See all bevacizumab litigation

Pharmacology for bevacizumab

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2024-05-28
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2035-07-14
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2029-03-11
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2034-03-14
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2035-07-11

2) High Certainty: US Patents for bevacizumab Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2014-01-25	Company disclosures
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2020-08-05	Company disclosures

3) Low Certainty: US Patents for bevacizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2035-03-27	Patent claims search
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2032-09-12	Patent claims search
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2035-12-11	Patent claims search
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2034-02-06	Patent claims search
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085		2035-03-30	Patent claims search

International Patents for bevacizumab

Country	Patent Number	Estimated Expiration
Japan	2012191936
Germany	69535133
Japan	4115517
European Patent Office	0678122
Japan	2010183907

Supplementary Protection Certificates for bevacizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2006/025	Ireland		PRODUCT NAME: NATALIZUMAB (ALSO KNOWN AS TYSABRI); REGISTRATION NO/DATE: EU/1/06/346/001 20060627
SPC 025/2006	Ireland		SPC 025/2006: 20070523, EXPIRES: 20200124
132006901471186	Italy		PRODUCT NAME: NATALIZUMAB(TYSABRI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/06/346/001, 20060627
SZ 23/2006	Austria		PRODUCT NAME: NATALIZUMAB
06C0024	France		PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627